Myasthenia Gravis Treatment Market Growth and Analysis 2034
Global Myasthenia Gravis Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Oct-2025 | Report ID: HLCA25324 | Pages: 1 - 259 | Formats*: |
| Category : Healthcare | |||
Global Myasthenia Gravis Treatment Market Introduction and Overview
According to SPER Market Research, the Global Myasthenia Gravis Treatment Market is estimated to reach USD 5.81 billion by 2034 with a CAGR of 9.25%.
The report includes an in-depth analysis of the Global Myasthenia Gravis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The global Myasthenia Gravis Treatment market was valued at USD 2.4 billion in 2024, and it is expected to rise at a 9.25% CAGR from 2025 to 2034. Myasthenia gravis treatment is being driven by advances in biotechnology, targeted biologic therapies, rising diagnosis rates, increased investment in orphan drugs, favorable regulations, expedited approvals, and an aging population that requires effective long-term management of autoimmune disorders. Meanwhile, the myasthenia gravis treatment industry is constrained by high treatment costs, insufficient reimbursement, limited healthcare infrastructure, lengthy regulatory approvals, and concerns about long-term safety and efficacy, which all limit accessibility, adoption, and consistent growth of therapies across regions.
By Treatment Type Insights
Medications can significantly suppress the immune system and effectively manage the resulting symptoms. Immunotherapies like Soliris (eculizumab) and corticosteroids, as well as immunosuppressive medicines like Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine), are used. The other primary treatment option is surgery, which is the most invasive and typically involves a thymectomy. The thymus deteriorates with age (thymic involution); nonetheless, full absence of the thymus will drastically decrease a patient's immunological response. The monoclonal antibodies segment had the biggest market share and is likely to keep its lead position during the projection period, owing to its high precision in treating myasthenia gravis and improved effectiveness.
By End User Insights
The market is divided into hospitals, clinics, and others based on end user. The hospital segment has the biggest market share in 2024. This can be attributable to a big patient pool and a significant demand for improved MG treatment equipment in hospitals. Patient visits for MG diagnosis and treatment have increased as a result of the availability of a diverse range of treatment choices in such facilities. Furthermore, rising investment in cutting-edge healthcare infrastructures is a big contributor to its large market share. The clinic segment held the second-largest share and is likely to maintain that position during the forecast period. With the increased demand for specialized treatments, many patients prefer to visit specialty clinics for a quick diagnosis and successful MG therapy.
Regional Insights
North America has the greatest market share and is expected to lead the market during the projection period. This can be due to the widespread use of immunotherapies and monoclonal antibodies, rising healthcare costs, the presence of established R&D facilities, and advantageous reimbursement scenarios.
The Middle East and Africa are predicted to expand at the quickest CAGR during the projection period. This is due to the rising prevalence of myasthenia gravis in the region, particularly among the elderly, increased awareness, the availability of better diagnostic equipment and therapy choices, and the expansion of healthcare infrastructure.
Market Competitive Landscape
Some of the market's top players, such as Alexion Pharmaceuticals, have the greatest market shares due to the high sales of their flagship medications, Soliris and Prograf. However, generic competition is a significant impediment to market expansion due to the patent loss of some marketed medicines and the availability of low-cost replacements for branded pharmaceuticals on the market. To obtain an advantage over competitors, corporations are implementing methods such as expanding into emerging markets, developing new products, raising awareness, and forming alliances. Furthermore, various market companies are conducting clinical trials to determine the efficacy of the medications for the illness.
Recent Developments:
In October 2023, UCB S.A., a worldwide biopharmaceutical firm, announced that ZILBRYSQ (zilucoplan) has been approved by the US FDA to treat generalized myasthenia gravis (gMG) in people who have anti-acetylcholine receptor (AChR) antibodies.
In September 2023, Recipharm AB teamed with AHEAD THERAPEUTICS S.L. to develop a novel medicine for myasthenia gravis. This agreement helps to increase the manufacturing capacity of myasthenia gravis products.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Treatment, By End User |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AbbVie Inc, Alexion Pharmaceutical Inc, Avadel Pharmaceuticals, Plc, Bausch Health Companies Inc, F.Hoffmann-La Roche AG, GlaxoSmithKline Plc, Grifols SA, Novartis, Pfizer, Inc, Shire plc. |
Key Topics Covered in the Report
- Global Myasthenia Gravis Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Myasthenia Gravis Treatment Market
- Segmentation of Global Myasthenia Gravis Treatment Market By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
- Segmentation of Global Myasthenia Gravis Treatment Market By End User (Hospitals, Clinics, Others)
- Statistical Snap of Global Myasthenia Gravis Treatment Market
- Expansion Analysis of Global Myasthenia Gravis Treatment Market
- Problems and Obstacles in Global Myasthenia Gravis Treatment Market
- Competitive Landscape in the Global Myasthenia Gravis Treatment Market
- Details on Current Investment in Global Myasthenia Gravis Treatment Market
- Competitive Analysis of Global Myasthenia Gravis Treatment Market
- Prominent Players in the Global Myasthenia Gravis Treatment Market
- SWOT Analysis of Global Myasthenia Gravis Treatment Market
- Global Myasthenia Gravis Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Myasthenia Gravis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Myasthenia Gravis Treatment Market
7.Global Myasthenia Gravis Treatment Market, By Treatment Type (USD Million) 2021-2034
7.1.Cholinesterase Inhibitors7.2.Chronic Immunomodulators7.3.Monoclonal Antibodies7.4.Rapid Immunotherapies7.5.Thymectomy7.6.Others
8.Global Myasthenia Gravis Treatment Market, By End User (USD Million) 2021-2034
8.1.Hospitals8.2.Clinics8.3.Others
9.Global Myasthenia Gravis Treatment Market, (USD Million) 2021-2034
9.1.Global Myasthenia Gravis Treatment Market Size and Market Share
10.Global Myasthenia Gravis Treatment Market, By Region, (USD Million) 2021-2034
10.1.Asia-Pacific
10.1.1.Australia10.1.2.China10.1.3.India10.1.4.Japan10.1.5.South Korea10.1.6.Rest of Asia-Pacific
10.2.Europe
10.2.1.France10.2.2.Germany10.2.3.Italy10.2.4.Spain10.2.5.United Kingdom10.2.6.Rest of Europe
10.3.Middle East and Africa
10.3.1.Kingdom of Saudi Arabia10.3.2.United Arab Emirates10.3.3.Qatar10.3.4.South Africa10.3.5.Egypt10.3.6.Morocco10.3.7.Nigeria10.3.8.Rest of Middle-East and Africa
10.4.North America
10.4.1.Canada10.4.2.Mexico10.4.3.United States
10.5.Latin America
10.5.1.Argentina10.5.2.Brazil10.5.3.Rest of Latin America
11.Company Profile
11.1.AbbVie Inc
11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments
11.2.Alexion Pharmaceutical Inc
11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments
11.3.Avadel Pharmaceuticals, Plc
11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments
11.4.Bausch Health Companies Inc
11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments
11.5.F.Hoffmann-La Roche AG
11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments
11.6.GlaxoSmithKline Plc
11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments
11.7.Grifols SA
11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments
11.8.Novartis
11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments
11.9.Pfizer, Inc
11.9.1.Company details11.9.2.Financial outlook11.9.3.Product summary11.9.4.Recent developments
11.10.Shire plc
11.10.1.Company details11.10.2.Financial outlook11.10.3.Product summary11.10.4.Recent developments
11.11.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Myasthenia Gravis Treatment Market is projected to reach USD 5.81 billion by 2034, growing at a CAGR of 9.25% during the forecast period.
Myasthenia Gravis Treatment Market size from 2025. The Market is expected to reach USD 5.81 billion by 2034, at a CAGR of 9.25% during the forecast period.
Myasthenia Gravis Treatment Market CAGR of 9.25% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Myasthenia Gravis Treatment Market size is USD 5.81 billion from 2025 to 2034.
Myasthenia Gravis Treatment Market covered By Treatment, By End User
The North America is anticipated to have the highest Market share in the Myasthenia Gravis Treatment Market.
AbbVie Inc, Alexion Pharmaceutical Inc, Avadel Pharmaceuticals, Plc, Bausch Health Companies Inc, F.Hoffmann-La Roche AG, GlaxoSmithKline Plc, Grifols SA, Novartis, Pfizer, Inc, Shire plc.
The report includes an in-depth analysis of the Global Myasthenia Gravis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
